Conference News Drug Discovery

Meeting Spotlight:  Modern Phenotypic Drug Discovery, May 22-25, 2022

0

socialQuote-E2-Jenkins-#KSDrugDiscovery22

The convergence of new technology platforms (including induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, and advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence, have led to an exciting renaissance of phenotypic drug discovery.

This meeting will integrate academic and industry approaches to PDD, covering evolving advances in new PDD technologies and biological models, across various human disease areas. The program will address critical barriers in the field, including how to improve the physiological relevance of phenotypic models, identifying phenotypic targets and mechanisms of action. Attendees will learn new techniques and tools to advance their research, and the field.

Program Highlights:

  • Applications of Modern Computational Techniques to PDD
  • Phenotypical Approaches to Tackling Infectious Disease
  • Novel Chemistry to Enable PDD
  • Innovative Cell and Animal Models to Advance PDD
  • Systems Biology Approaches to Chemical Biology
  • Advances in Approaches to Understand Mechanism of Action

Featuring presentations by industry  leaders including Genentech, Abbvie, Merck, Novartis and more!

click-to-tweet-icon


Find out more!

2400x800_2022E2-KSDrugDiscovery22

 

Keypoint-Logo_Blog_BLACK

 
Shannon Weiman
Shannon Weiman earned her PhD in Biomedical Sciences from the University of California, San Diego, specializing in microbiology and immunology. Prior to joining the Keystone Symposia team, she worked as a freelance writer for leaders in academic, industry and government research, including Stanford University’s Biomedical Innovation Initiative, the University of Colorado’s Biofrontiers Program, UCSF, the FDA and the American Society for Microbiology.
Prev
Next

Related news